

Jakub Rosik

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1138143/jakub-rosik-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20
papers

459
citations

12
h-index

21
g-index

22
ext. papers

753
ext. citations

7
avg. IF

4.22
L-index

#	Paper	IF	Citations
20	FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. <i>Drug Resistance Updates</i> , 2020 , 53, 100719	23.2	79
19	COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	77
18	Betulin and its derivatives as novel compounds with different pharmacological effects. <i>Biotechnology Advances</i> , 2020 , 38, 107409	17.8	73
17	Pleiotropic effects of statins: A focus on cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020 , 1866, 165968	6.9	40
16	COVID-19: Pain Management in Patients with SARS-CoV-2 Infection-Molecular Mechanisms, Challenges, and Perspectives. <i>Brain Sciences</i> , 2020 , 10,	3.4	26
15	Aspirin and its pleiotropic application. <i>European Journal of Pharmacology</i> , 2020 , 866, 172762	5.3	23
14	New therapies for the treatment of heart failure: a summary of recent accomplishments. <i>Therapeutics and Clinical Risk Management</i> , 2019 , 15, 147-155	2.9	22
13	An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.. <i>Drug Resistance Updates</i> , 2021 , 100794	23.2	20
12	COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients. <i>Clinical Interventions in Aging</i> , 2020 , 15, 1231-1240	4	18
11	The role of genetics and epigenetics in the pathogenesis of gestational diabetes mellitus. <i>Annals of Human Genetics</i> , 2020 , 84, 114-124	2.2	17
10	Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets. <i>Cancers</i> , 2021 , 13,	6.6	15
9	CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 149-159	5.9	14
8	Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 617-626	5.5	9
7	Potential targets of gene therapy in the treatment of heart failure. <i>Expert Opinion on Therapeutic Targets</i> , 2018 , 22, 811-816	6.4	6
6	Kidney damage from nonsteroidal anti-inflammatory drugs-Myth or truth? Review of selected literature. <i>Pharmacology Research and Perspectives</i> , 2021 , 9, e00817	3.1	6
5	The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2020 , 15, 85-99	6.2	5
4	Reprogramming and transdifferentiation - two key processes for regenerative medicine. <i>European Journal of Pharmacology</i> , 2020 , 882, 173202	5.3	4

3	The Role of BiP and the IRE1/XBP1 Axis in Rhabdomyosarcoma Pathology. <i>Cancers</i> , 2021 , 13,	6.6	4
2	Human Cell Organelles in SARS-CoV-2 Infection: An Up-to-Date Overview. <i>Viruses</i> , 2022 , 14, 1092	6.2	1
1	Umbilical cord blood transplantation and the impact of the CTLA4 genotype on outcomes. <i>Expert Review of Hematology</i> , 2019 , 12, 1089-1094	2.8	0